New research out of VCU Massey Cancer Center suggests that the inactivation of NF1—a gene known as Neurofibromin-1 that holds natural tumor-suppressing functions—could be instrumental in the onset of pancreatic cancer, either in tandem with KRAS mutations, which occur in 85-90% of all pancreatic tumors, or even before any mutations occur in the KRAS gene, in partnership with TP53, the most inactivated tumor suppressor gene in human malignancies.
Lisa G. Roth was named director of the Division of Pediatric Hematology-Oncology at Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center. Roth is a pediatric oncologist, physician-scientist, and lymphoma survivor.
